Recruiting eligible patients for F4 MASH clinical trials is increasingly challenging due to the underdiagnosis of both MASH and compensated cirrhosis, as well as common eligibility barriers that can limit enrollment.

This white paper analyzes real-world patient data to estimate the size of the potential participant pool, identify overlooked recruitment opportunities, and provide practical strategies to improve site selection, prescreening, and enrollment outcomes